TY - JOUR
T1 - Myeloid cell leukemia-1 dependence in acute myeloid leukemia
T2 - A novel approach to patient therapy
AU - Kadia, Tapan Mahendra
AU - Kantarjian, Hagop M.
AU - Konopleva, Marina
N1 - Funding Information:
by Adelphi Communications, New York, NY and Ashfield Healthcare Communications, part of UDG Healthcare plc, Dublin, Ireland, and were funded by Boston Biomedical, Inc., Cambridge, MA. None of the named authors received any compensation for their contributions to this work.
Publisher Copyright:
© PeerJ Inc. All rights reserved.
PY - 2019/2/1
Y1 - 2019/2/1
N2 - Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, affecting approximately 21,000 people annually (nearly 11,000 deaths) in the United States. B-cell lymphoma 2 (BCL-2) family proteins, notably myeloid cell leukemia-1 (MCL-1), have been associated with both the development and persistence of AML. MCL-1 is one of the predominant BCL-2 family members expressed in samples from patients with untreated AML. MCL-1 is a critical cell survival factor for cancer and contributes to chemotherapy resistance by directly affecting cell death pathways. Here, we review the role of MCL-1 in AML and the mechanisms by which the potent cyclin-dependent kinase 9 inhibitor alvocidib, through regulation of MCL-1, may serve as a rational therapeutic approach against the disease.
AB - Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, affecting approximately 21,000 people annually (nearly 11,000 deaths) in the United States. B-cell lymphoma 2 (BCL-2) family proteins, notably myeloid cell leukemia-1 (MCL-1), have been associated with both the development and persistence of AML. MCL-1 is one of the predominant BCL-2 family members expressed in samples from patients with untreated AML. MCL-1 is a critical cell survival factor for cancer and contributes to chemotherapy resistance by directly affecting cell death pathways. Here, we review the role of MCL-1 in AML and the mechanisms by which the potent cyclin-dependent kinase 9 inhibitor alvocidib, through regulation of MCL-1, may serve as a rational therapeutic approach against the disease.
KW - AML
KW - Alvocidib
KW - BCL-2
KW - Flavopiridol
KW - MCL-1
UR - http://www.scopus.com/inward/record.url?scp=85061358599&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061358599&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.26579
DO - 10.18632/oncotarget.26579
M3 - Review article
C2 - 30815228
AN - SCOPUS:85061358599
SN - 1949-2553
VL - 10
SP - 1250
EP - 1265
JO - Oncotarget
JF - Oncotarget
IS - 12
ER -